首页> 外文期刊>Annals of surgical oncology >Intraoperative radiofrequency ablation for hepatocellular carcinoma: long-term results in a large series.
【24h】

Intraoperative radiofrequency ablation for hepatocellular carcinoma: long-term results in a large series.

机译:术中射频消融治疗肝细胞癌:长期的大量研究结果。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Intraoperative radiofrequency (RF) ablation with or without surgical resection currently plays one of important roles in modern hepatocellular carcinoma (HCC) therapy. We evaluated long-term follow-up results including prognostic factors of intraoperative RF ablation for HCC that was difficult to treat percutaneously. METHODS: A total of 133 patients (male, 22 female, mean age 55.8 years) underwent intraoperative RF ablations for 200 HCCs (follow-up period 3.0-79.7 months, median 22.3 months). Hepatic resection was also performed in 29 patients. Reasons for the intraoperative procedure included no safe electrode path (n = 59), excessive tumor burden (n = 41), nonvisualization of the HCC on ultrasonography (n = 20), and risk of collateral thermal damage to adjacent organs (n = 13). We evaluated the technique effectiveness rate at 1 month computed tomography (CT), cumulative local tumor progression rate, cumulative disease-free and overall survival rates, and complications. We also sought significant prognostic factors for overall survival. RESULTS: The technique effectiveness at 1 month was 94.7% (126/133). The cumulative local tumor progression rates at 1 and 3 years were 4.9% and 8.8%, respectively. The cumulative disease-free and overall survival rates at 1, 3 and 5 years were 51.8%, 21.3%, and 16.0% and 92.3%, 72.6%, and 46.5%, respectively. Major complications occurred in nine patients (6.8%). Procedure-related mortality was 1.5% (2/133). The patients treated for recurrent HCC (P = 0.003) or with high serum alpha-fetoprotein levels (P = 0.009) had poor survival by multivariate analysis. CONCLUSION: The results of this study showed that intraoperative radiofrequency ablation with or without hepatic resection is a safe and effective treatment for hepatocellular carcinoma in patients who are not candidates for the percutaneous approach.
机译:背景:术中射频消融术或不进行手术切除术目前在现代肝细胞癌(HCC)治疗中起着重要作用。我们评估了长期随访结果,包括术中射频消融治疗HCC的预后因素,这些因素难以经皮治疗。方法:共有133例患者(男22例,平均年龄55.8岁)接受了200例HCC的术中射频消融(随访期3.0-79.7个月,中位数22.3个月)。还对29例患者进行了肝切除。术中操作的原因包括:没有安全的电极路径(n = 59),过多的肿瘤负担(n = 41),在超声检查中无法看到HCC(n = 20)以及对相邻器官造成附带热损害的风险(n = 13) )。我们评估了1个月计算机断层扫描(CT)的技术有效率,局部肿瘤累积进展率,无病累积和总生存率以及并发症。我们还寻求总体生存的重要预后因素。结果:1个月的技术有效性为94.7%(126/133)。 1年和3年累积的局部肿瘤进展率分别为4.9%和8.8%。在1年,3年和5年的无病累积生存率和总生存率分别为51.8%,21.3%和16.0%,92.3%,72.6%和46.5%。主要并发症发生在9名患者中(6.8%)。与手术相关的死亡率为1.5%(2/133)。经多因素分析,接受复发性肝癌治疗(P = 0.003)或血清甲胎蛋白水平高(P = 0.009)的患者生存期较差。结论:这项研究的结果表明,术中射频消融加或不加肝切除术是不适合经皮入路的肝细胞癌的安全有效治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号